Cure My Disease

Don't miss your cure!

 Log in / Sign up

A watchful eye: could alternating scans outsmart pancreatic cancer?

NCT ID NCT02206360

Diagnosis Sponsor: White Plains Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 25, 2026 · Last updated Aug 26, 2026 · Updated 1 time

Summary

This study follows people with a significantly elevated risk of pancreatic cancer—due to inherited gene mutations or strong family history—who choose to undergo early detection testing. Participants receive endoscopic ultrasound (EUS) and MRI scans on an alternating schedule every 6 to 12 months for up to 5 years. The goal is to see whether this approach can find premalignant or malignant pancreatic conditions early, potentially improving outcomes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Alternating endoscopic ultrasound (EUS) and magnetic resonance imaging (MRI) scans
What this could lead to
If this works, it could show that regular alternating scans help catch pancreatic cancer at an earlier, more treatable stage in high-risk individuals.
What could go wrong
This is an observational study, not a randomized trial, so it can't prove the scans improve survival. The procedures carry risks like sedation or complications from sedation or the scope, and the results may not apply to everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

181 people

The number who actually took part.

Started

Apr 2014

Finished

Aug 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Individuals aged 18 and older, who carry sufficiently elevated risk for the development of pancreatic cancer, numerically defined as over (or near) 5 times the general population risk, as determined by their personal, familial, or genetic history.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Any of the following: 1. Known carrier of either the BRCA2 or CDKN2A mutation; 2. Known carrier of any of the following mutations (BRCA1, MLH1, MSH2, PMS2, MSH6, EPCAM , P53, PALB2, APC, or ATM) PLUS first or second degree relative affected with pancreatic cancer; 3. Individual with Peutz-Jeghers Syndrome; 4. Familial Pancreatic Cancer, defined as at least two affected relatives with Pancreatic Cancer, who are first degree relatives with each other, and at least one of those affected must be first degree relative to the study subject; 5. Both parents affected, any age: 6. Any first degree relative diagnosed with pancreatic cancer under age 50; 7. Chronic Pancreatitis Syndrome, defined by either PRSS1 or SPINK1 mutations AND appropriate clinical and family history Exclusion Criteria: 1. Any medical condition that contraindicates endoscopy or biopsy 2. Any medical condition that contraindicates MRI 3. Status post partial or complete resection of the pancreas 4. History of pancreatic cancer, either endocrine or exocrine 5. Clinical suspicion of pancreatic cancer, or any previous radiographic or histologic diagnosis of a pre-malignant finding, including IPMN (Intraductal papillary mucinous neoplasm) and PanIN (Pancreatic intraepithelial Neoplasm). 6. diagnosis of dementia 7. Uncontrolled, current illness 8. Renal insufficiency with serum creatinine greater than 2.0 mg/dl

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BRCA 1/2 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Colorectal Neoplasms, Hereditary Nonpolyposis familial atypical multiple mole melanoma syndrome familial pancreatic carcinoma hereditary chronic pancreatitis hereditary nonpolyposis colon cancer Lynch syndrome malignant pancreatic neoplasm melanoma, cutaneous malignant, susceptibility to, 2 pancreatic adenocarcinoma pancreatic neoplasm Peutz-Jeghers syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BRCA 1/2 Familial atypical multiple mole melanoma Familial pancreatic cancer FAMMM Hereditary pancreatitis HNPCC Lynch syndrome Pancreas cancer Pancreatic adenocarcinoma Pancreatic cancer Peutz Jeghers syndrome

Contacts and locations

Locations

  • White Plains Hospital

    White Plains, New York, 10601, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.